咪喹莫特和重组人干扰素α-2b对尖锐湿疣的总疣体数、临床疗效、复发情况和局部表皮郎格罕斯细胞数量疗效比较  

Comparison of the efficacy of imiquimod and recombinant human interferon α-2b on the warts amount, clinical efficacy, recurrence rate and local epidermal langerhans cell amount in patients with condyloma acuminate

作　　者：欧伟洪 王薇[1] 陈晓东[2] OU Weihong;WANG Wei;CHEN Xiaodong(Department of Dermatology ,Central South University Xiangya School of Medicine Affiliated Haikou Hospital,Haikou 570208,Hainan,China;Department of Neurosurgery,Central South University Xiangya School of Medicine Affiliated Haikou Hospital,Haikou 570208, Hainan,China)

机构地区：[1]中南大学湘雅医学院附属海口医院皮肤科,海口570208 [2]中南大学湘雅医学院附属海口医院神经外科,海口570208

出　　处：《中国性科学》2019年第4期133-136,共4页Chinese Journal of Human Sexuality

基　　金：海南省卫生厅科研课题项目(琼卫2011-57)

摘　　要：目的比较咪喹莫特和重组人干扰素α-2b对尖锐湿疣的总疣体数、临床疗效、复发情况和局部表皮郎格罕斯细胞数量疗效。方法选取2015年12月至2017年9月中南大学湘雅医学院附属海口医院诊治的86例尖锐湿疣患者,按照随机数字表法将其平均分为研究组和对照组,每组43例患者。所有患者均进行激光治疗,在此基础上研究组使用咪喹莫特治疗,对照组使用重组人干扰素α-2b治疗。比较两组患者治疗总有效率、治疗前后总疣体数、复发率、皮郎格罕斯细胞数量及并发症发生率的差异。结果研究组患者治疗总有效率为95.3%,高于对照组患者的79.1%,组间差异具有统计学意义(P<0.05)。两组患者治疗前总疣体数比较,其差异无统计学意义(P>0.05)。治疗后4周、治疗后8周、结束治疗后2周,两组患者总疣体数均比治疗前有所降低(均P<0.05);研究组患者总疣体数均少于对照组患者,组间差异均具有统计学意义(均P<0.05)。治疗后随访3个月内,研究组患者复发率为2.3%,对照组患者复发率为18.6%,研究组患者复发率低于对照组患者,组间差异具有统计学意义(P<0.05)。治疗前,两组患者表皮郎格罕斯细胞染色强度灰度值比较,其差异无统计学意义(P>0.05);治疗后1个月、2个月、3个月,两组患者表皮郎格罕斯细胞染色强度灰度值均比治疗前有所升高(均P<0.05),研究组患者表皮郎格罕斯细胞染色强度灰度值均高于对照组患者(均P<0.05)。研究组和对照组患者并发症发生率分别为7.0%、11.6%,组间差异无统计学意义(P>0.05)。结论咪喹莫特治疗尖锐湿疣效果好,在疣体清除情况、复发情况和局部表皮郎格罕斯细胞数量等方面优于重组人干扰素α-2b。Objective To compare the efficacy of imiquimod and recombinant human interferon α-2 b on the warts amount, clinical efficacy, recurrence and local epidermal langerhans cells amount in patients with condyloma acuminate(CA). Methods 86 CA patients in Central South University Xiangya School of Medicine Affiliated Haikou Hospital from December 2015 to September 2017 were randomly divided into control group(treated with recombinant human interferon α-2 b) and research group(treated with imiquimod). The warts amount, total treatment effective rate, recurrence rate, local epidermal cells amount and complication rate of the two groups were compared. Results The total treatment effective rate of research group and control group was 95.3% and 79.1% respectively, with statistically significant difference(P<0.05). There was no statistically significant difference in the warts amount between the two groups before treatment(P>0.05), but the warts amount of research group was smaller than that of the control group after 4 and 8 weeks of treatment and at 2 weeks after the end of treatment, with statistically significant differences(all P<0.05). Within 3 weeks after treatment, the recurrence rate of research group and control group was 2.3% and 18.6% respectively, with statistically significant difference(P<0.05). There was no statistically significant difference in langerhans cell staining intensity gray value between the two groups before treatment(P>0.05), while the langerhans cell staining intensity gray value of research group was higher than that of the control group in the first three months after treatment( all P<0.05). The complication rate of research group and control group was 7.0% and 11.6% respectively, without statistically significant difference between the two groups(P>0.05). Conclusions Imiquimod is of remarkable effect for patients with CA, which is better than recombinant human interferon α-2 b in wart removal, recurrence rate and local epidermal langerhans cell amout.

关 键 词：咪喹莫特 重组人干扰素 尖锐湿疣 郎格罕斯细胞 

分 类 号：R759[医药卫生—皮肤病学与性病学]